You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Polymeric Trileaflet Heart Valve Prosthesis
SBC: ABIOMED, INC. Topic: N/ADESCRIPTION (provided by applicant): The development of a durable, hemocompatible valve prosthesis is the long-term objective of this proposal. While heart valve prostheses have been used successfully since 1960, 10-year survival rates still range from
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Fail-safe TET system for implanted life support devices
SBC: ABIOMED, INC. Topic: N/ADESCRIPTION (provided by applicant): Cardiac assist devices are increasingly being used for long term support. As patient survival times increase substantially, long-term management of the patients will increasingly play a role in suitability of these
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
A Smart Polymer for Destination Cardiac Assist Devices
SBC: ABIOMED, INC. Topic: N/ADESCRIPTION (provided by applicant): Cardiac assist devices are increasingly being used for long term support. As patient survival times increase substantially, device wear-out will increasingly play a role in the clinical management of patients with l
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Three Dimensional ECM Scaffolds for Tissue Engineering
SBC: ACELL, INC. Topic: N/ADESCRIPTION (provided by applicant): This Phase I SBIR application seeks support to develop a three dimensional acellular scaffold composed of particulate extracellular matrix (ECM). Products composed of the two dimensional (sheet form) of ECM der
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Novel A2A Adenosine Agonists in Vascular Protection
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine Therapeutics (compound synthesis and pharmacokinetics) and the University of Virginia (Stent studies in pigs) ...
STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Antagonists of A2B Receptors Improve Insulin Sensitivity
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): This is a phase II SBIR grant to develop a new therapy for the treatment of type II diabetes. Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
A2A Adenosine Receptor Agonist for the Treatment of IBD
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): Adenosine Therapeutics, LLC (ATL) is a biotechnology company started in Charlottesville, Virginia in 1999. ATL owns patents on the formulation and use of a family of potent and highly selective agonists of A2A adenosin
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
New Agents That Inhibit Fatty Acid Accumulation
SBC: ADIPOGENIX, INC. Topic: N/ADESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing treatments for obesity are only modestly effective. The mission of AdipoGenix, Inc. is
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Blockers of B. anthracis Toxin
SBC: Innovative Biologics Inc. Topic: N/ADESCRIPTION (provided by investigator): Results from our SBIR Phase I project demonstrated that beta-cyclodextrin derivatives designed to block the trans-membrane channel formed by B. anthracis protective antigen (PA) can inhibit the cytotoxic effects
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Impedance based knee simulation control
SBC: Advanced Mechanical Technology, Inc. Topic: N/ADESCRIPTION (provided by applicant): Over 299,000 total knee replacement procedures were conducted in 2002 with projections to 474,000 by 2030. It is estimated that the annual cost of TKR exceeds $6 billion in the US. Despite the success of TKR revisi
SBIR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health